When your patent is about to expire and generic competitors are circling, there's really only one move: cut prices first and hope to keep customers loyal. That's exactly what Novo Nordisk (NVO) is doing in China, slashing Wegovy prices by roughly 50% before local generics flood the market.
According to local media reports cited by Bloomberg on Monday, the Danish pharmaceutical giant reduced prices for its two highest Wegovy doses to 987.48 yuan (about $141) and 1,284.36 yuan in provinces including Yunnan and Sichuan. These new prices showed up in government drug-procurement documents, making the cuts official.
Novo's explanation? The company says it wants to ease patient costs and support treatment adherence. Which is true, but there's also the small matter of Novo's semaglutide patent in China expiring in March. Once that happens, the door swings wide open for cheaper local generics to compete head-to-head with Wegovy.
The price reductions aren't limited to government channels either. JD.com (JD), the e-commerce giant, has already lowered Wegovy prices on its online pharmacy platform, letting patients nationwide order the drug following an online medical consultation. So whether you're in Yunnan or anywhere else in China, cheaper Wegovy is now within reach.
Competition Heating Up Across Asia
The timing of these price cuts isn't coincidental. Competitive pressure has been building since China approved a domestically developed obesity drug from Innovent Biologics Inc. (IVBXF). That approval adds another layer to the already intense global rivalry between Novo Nordisk and Eli Lilly and Co (LLY), which are battling for dominance in the lucrative obesity treatment market.
But China isn't the only Asian market where Novo is making aggressive moves. In December, the company launched Ozempic in India, pricing the weekly 0.25 mg dose at $24.35 as it pushes into what's become one of the world's most important diabetes and obesity markets.
According to Reuters, Ozempic will be available in pen formats across three strengths: 0.25 mg, 0.5 mg, and 1 mg, with monthly pricing set at 8,800 rupees, 10,170 rupees, and 11,175 rupees respectively. Each pen contains four weekly doses, making the math simple for patients planning their treatment costs.
Analysts expect these India prices to essentially set the benchmark for semaglutide generics scheduled to arrive next quarter. India represents the second-largest market for type 2 diabetes after China, making it a critical expansion opportunity that Novo can't afford to botch.
Eli Lilly Builds Its Own India Strategy
Meanwhile, Eli Lilly isn't sitting idle. Back in October, the pharmaceutical giant announced plans to invest over $1 billion in India to strengthen its manufacturing network there.
Lilly's approach differs from building its own facilities. The company currently doesn't operate its own manufacturing plants in India, instead planning to work contractually with local firms that produce complex drugs, vials, and injectables. It's a partnership strategy that could give Lilly flexibility while avoiding the massive capital requirements of building from scratch.
The stakes are enormous. Both companies are racing to dominate markets where hundreds of millions of patients struggle with diabetes and obesity. Price cuts, strategic launches, manufacturing investments—these are the opening moves in what's shaping up to be a prolonged battle for market share across Asia.
As for Novo's stock, investors weren't thrilled with the Chinese price cuts. Shares were down 1.35% at $51.69 at the time of publication on Monday, according to market data.
